BCI
TXMD icon

Brinker Capital Investments’s TherapeuticsMD TXMD Stock Holding History

Brinker Capital Investments’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-60
Closed -$8K – 946
2019
Q2 		$8K Buy
+60
New +$10.8K ﹤0.01% 807

Other funds holding TXMD

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brinker Capital Investments's TXMD Position: Q3 2019 in Review

Brinker Capital Investments sold out of TherapeuticsMD (TXMD) in Q3 2019, closing a stake of 60 shares — an estimated $8K sold.

Brinker Capital Investments first reported a position in TXMD in Q2 2019 and held it in 1 quarter. The position peaked at $8K in Q2 2019. 150 funds tracked by Wall St. Rank hold TXMD as of Q3 2019.

  • Brinker Capital Investments reported no remaining TherapeuticsMD position as of Q3 2019 after selling out during the quarter.
  • Brinker Capital Investments sold 60 TherapeuticsMD shares in Q3 2019, an estimated $8K.
  • Brinker Capital Investments first reported a position in TherapeuticsMD in Q2 2019 and held it in 1 quarter.
  • Brinker Capital Investments's TherapeuticsMD position peaked at $8K in Q2 2019.
  • 150 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2019.

Based on Brinker Capital Investments's 13F filing for Q3 2019, filed 14 Nov 2019.